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 Review Article
In South Korea, as in many other countries, propofol sedation is performed by practitioners across a broad range of spe-
cialties in our country. However, this has led to significant variation in propofol sedation practices, as shown in a series of 
reports by the Korean Society of Anesthesiologists (KSA). This has led the KSA to develop a set of evidence-based practi-
cal guidelines for propofol sedation by non-anesthesiologists. Here, we provide a set of recommendations for propofol 
sedation, with the aim of ensuring patient safety in a variety of clinical settings. The subjects of the guidelines are patients 
aged ≥ 18 years who were receiving diagnostic or therapeutic procedures under propofol sedation in a variety of hospital 
classes. The committee developed the guidelines via a de novo method, using key questions created across 10 sub-themes 
for data collection as well as evidence from the literature. In addition, meta-analyses were performed for three key ques-
tions. Recommendations were made based on the available evidence, and graded according to the modified Grading of 
Recommendations Assessment, Development and Evaluation system. Draft guidelines were scrutinized and discussed by 
advisory panels, and agreement was achieved via the Delphi consensus process. The guidelines contain 33 recommenda-
tions that have been endorsed by the KSA Executive Committee. These guidelines are not a legal standard of care and 
are not absolute requirements; rather they are recommendations that may be adopted, modified, or rejected according to 
clinical considerations.
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Introduction
Because of the favorable pharmacokinetic profile of propofol 
(i.e., rapid onset of action and short recovery time), it has been 
widely used for sedation by practitioners across a broad range of 
specialties. In contrast to the agents used for traditional sedation 
(i.e., benzodiazepines and/or opioids), propofol can easily lead 
to deep sedation or even general anesthesia requiring cardio-
pulmonary support. A series of reports by the Korean Society 
of Anesthesiologists (KSA) found that the number of disputed 
medical cases involving propofol sedation has increased in 
recent years, and the magnitude of injuries associated with pro-
pofol sedation is similar to those with general anesthesia [1,2]. 
Significant variation in propofol sedation practices was also 
found across different types of procedures, clinical specialties, 
and hospital classes.
In response to these issues, the KSA developed evidence-based 
practical guidelines for propofol sedation by non-anesthesiolo-
gists (anesthesiologists have specific expertise in the pharmacol-
ogy, physiology, and clinical management of patients receiving 
propofol sedation). Here, we describe a set of recommenda-
tions for ensuring patient safety in a variety of clinical settings. 
These guidelines were formulated via a de novo method, which 
involved a systematic review of the available evidence and a 
synthesis of expert opinion. These guidelines are neither legal 
standards of care nor absolute requirements; therefore, clinical 
considerations may lead a practitioner to take a course of action 
that varies from these guidelines. 
Methodology
Definitions of ‘propofol sedation’ and ‘level of sedation’
Propofol sedation is defined as a technique of administering 
propofol with or without other sedatives/analgesics to induce a 
state that allows patients to tolerate unpleasant procedures while 
maintaining cardiorespiratory function. Although the level of 
sedation can be assessed using different scales, here we followed 
the definitions of levels of sedation and anesthesia given by the 
American Society of Anesthesiologists (ASA) (Table 1) [3].
Scope
The subjects of this work were adult patients (i.e., aged ≥ 18 
years) receiving diagnostic or therapeutic procedures under pro-
pofol sedation in a variety of hospital classes (including primary, 
secondary, and tertiary healthcare classes). These guidelines 
were originally intended to provide useful information and 
guidance for all of the Korean non-anesthesiologist practitioners 
who perform propofol sedation. However, below we list some 
situations that we excluded from the scope of the guidelines:
- sedation in intensive care units;
- sedation for patients with artificial airways;
- sedation for dental procedures;
- palliative sedation at the end-of-life;
- and intended use of propofol for general anesthesia.
Methods used to develop guidelines
Fig. 1 shows a summary of the process used to develop these 
guidelines. The KSA appointed a Task Force of five members 
to determine the scope of the guidelines, create key questions 
in 10 sub-themes for data collection, systemically review the 
published data, make draft recommendations with supporting 
evidence, and draft the guidelines.
Because there were no existing evidence-based guidelines 
consistent to our scope, these guidelines were developed de 
novo. Two similar sets of guidelines for propofol sedation did 
exist; however, their scopes were limited to gastrointestinal (GI) 
endoscopy [4,5].
The Task Force team systematically collected and reviewed 
the international and domestic published literature using the 
PubMed, Cochrane, Embase, Scopus, KoreaMed, and Google 
Scholar databases. The literature was limited to publications 
before December 31, 2015, studies performed on adult patients, 
and studies published in the English or Korean languages. 
Table 1. Levels of Sedation and Anesthesia as Defined by the ASA [3]
Minimal sedation Moderate sedation Deep sedation General anesthesia
Responsiveness Normal response to  
verbal stimulation
Purposeful response to 
verbal or tactile 
stimulation
Purposeful response after 
repeated or painful 
stimulation
Unarousable even with 
painful stimulus
Airway Unaffected No intervention required Intervention may be  
required
Intervention often  
required
Spontaneous ventilation Unaffected Adequate May be inadequate Frequently inadequate
Cardiovascular function Unaffected Usually maintained Usually maintained May be impaired
American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia 
by non-anesthesiologists. Anesthesiology 2002; 96: 1004-17. ASA: American Society of Anesthesiologists.
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When a more recent systematic review or meta-analysis study 
was found, studies with a lower level of evidence were excluded. 
When there was no existing systematic review or meta-analysis 
of the high-ranked key questions (which were selected based on 
9-point Likert scale), additional meta-analyses were performed 
(see recommendations 19, 21, 22).
Level of evidence and grade of recommendation
The evidence levels used in these guidelines were determined 
using the University of Michigan Health System (UMHS) meth-
od, whereby the validity of an individual study was only based 
on an assessment of the study design (Table 2). The strength of 
a recommendation was determined according to the modified 
Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) system (Table 3). In addition to the level 
of evidence, the results of the studies were considered based on 
aspects of the clinical usefulness and trade-offs between health 
outcomes and patient benefit on the one hand, and the risks, dif-
ficulties, and costs on the other.
Review and guidelines determination process
The guidelines were drafted with recommendations that were 
initially suggested by the Task Force team, and were individu-
ally reviewed by all of the advisory panels prior to approval at a 
consensus meeting; the Delphi method was used to arrive at a 
consensus [6]. The advisory committee for the Delphi consensus 
process comprised 14 panelists who were members of the KSA 
Executive Committee. The agreement for each recommenda-
tion was graded according to the following response scale: 1–3, 
disagree; 4–6, uncertain, 7–9, agree. If over 50% of the panel re-
plied with a response of 7–9, a panel consensus was considered 
achieved. Of the 34 total recommendations, a consensus was 
reached on 32 of them in the first round, one recommendation 
required additional revision (recommendations 15) in a second 
round, and the remaining recommendation was eventually dis-
carded. The selected recommendations were incorporated into 
the final draft of the guidelines, and approved by the KSA Ex-
ecutive Committee.
Constitution of the guideline developing group
(5-member propofol TFT)
Determination of the scope (intended subjects and users)
Creation of the key questions (for data collection)
Search and review of evidences
: systemic review and meta-analysis ( )if applicable
: guidelines draft (written by the propofol TFT)
Determination of the final recommendations
: Delphi consensus rounds of the KSA advisory committee
Approval of the guidelines
(by the Executive Committee of the KSA)
Fig. 1. Schematic diagram of the overall process used to determine the 
guideline. TFT: Task Force tram, KSA: Korean Society of Anesthesiologists.
Table 2. Definition of the Levels of Evidence in the Guidelines
Level of evidence Definition
A Evidence obtained from at least one randomized controlled trial or systematic review/meta-analysis
B Evidence obtained from at least one well-designed case-control or cohort trial without randomization
C Evidence obtained from observational trials (case reports or case series)
D Evidence obtained from opinion of expert panels
Table 3. Definition of the Recommendation Grade in the Guidelines
Grade of  
recommendation Definition Description
Class 1 High level of evidence (A), substantial net benefit, and high clinical applicability Is recommended
Class IIa Confident level of evidence (B) and net benefit, and high or moderate clinical applicability Should be considered
Class IIb Uncertain level of evidence (C or D) and net benefit, and high or moderate clinical applicability May be considered
Class III Uncertain level of evidence (C or D), maybe harmful, and low clinical applicability Is not recommended
Although the class of recommendations was mainly determined based on the level of evidence, some could be downgraded or upgraded by the 
advisory panels, based on further consideration of net benefit or clinical applicability.
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Independence of support and editing
During the development of these guidelines, there was no 
external influence from any other academies, institutions, or 
interest groups. During the planning of the guidelines, members 
of relevant academies, institutions, or organizations (although 
they may have been intended users of the guidelines) were not 
allowed to participate in the development of these guidelines 
because of potential significant and direct interests in the out-
come of the guidelines. In 2015, the Korean Medical Association 
(KMA) attempted to develop a similar set of guidelines (i.e., 
practical guidelines for propofol sedation by non-anesthesiolo-
gist practitioners in a primary healthcare class) with participa-
tion from various stakeholders. However, those guidelines were 
influenced by these interest groups, and as such, many of the 
recommendations appeared arbitrary and were criticized for 
lacking impartiality. All of the members who participated in the 
development of these guidelines signed agreements confirming 
that there were no conflicts of interest in connection with this 
work.
Funding source
The development of these guidelines was supported by a 
grant from the Clinical Research Infrastructure Composition 
Project (project title: Patient Safety Policy Research) from the 
Korean Ministry of Health and Welfare.
Release of the guidelines and plan for updates
The (more detailed) Korean language version of the guide-
lines was released and published in June 2016 on the KSA 
website (http://www.anesthesia.or.kr/guidelines). Further 
documentation related to propofol sedation is also available on 
the website including informed consent forms, pre-sedation 
evaluation records, sedation records, and post-sedation recovery 
records. Given the rapid pace of changes in this field, updates 
to the guidelines are planned to be released at intervals of 3–5 
years. 
Contents
Propofol sedation vs. traditional sedation
Recommendation 1: Compared to traditional sedation, pro-
pofol sedation presents similar rates of adverse cardiorespiratory 
effects in low- or average-risk patients undergoing GI endoscopic 
procedures (Evidence level: A, Recommendation grade: Class I).
Recommendation 2: The above statement is valid for proce-
dures with a relatively short duration or for less invasive proce-
dures in other clinical fields (Evidence level: C, Recommendation 
grade: Class IIa).
Recommendation 3: In terms of cost-effectiveness, propofol 
sedation is superior to traditional sedation (Evidence level: D, Rec-
ommendation grade: Class III).
Commentary
Several meta-analyses [7-11] have shown clinical advantages 
of propofol sedation for GI endoscopy over traditional sedation 
with similar rates of adverse events (apnea, hypoxemia, hypoten-
sion, or arrhythmia). However, these results should be carefully 
interpreted in that all of the included studies were performed in 
a GI endoscopy setting, and most sedation cases were well con-
trolled (e.g., independent monitoring of relatively well-trained 
medical personnel and adequate levels of intra-procedural mon-
itoring). Therefore, such results may not be directly applicable to 
other clinical fields or poorly controlled clinical environments. 
In addition, considering the pharmacological characteristics of 
propofol, it is clear that poorly controlled propofol sedation car-
ries elevated risks of adverse cardiorespiratory effects compared 
to traditional sedation [12,13].
Pre-procedural preparation and assessment
Recommendation 4: In patients who chronically receive ben-
zodiazepines, barbiturates, anticonvulsants, or alcohol, the dose 
requirements of propofol may be increased (Evidence level: C, Rec-
ommendation grade: Class IIb).
Recommendation 5: Propofol sedation in the first trimester 
should be avoided if at all possible (Evidence level: C, Recommen-
dation grade: Class IIa).
Recommendation 6: No interruption of breastfeeding is re-
quired following propofol sedation (Evidence level: B, Recommen-
dation grade: Class IIa).
Commentary
Propofol is classified as a ‘category B’ drug by the United 
States Food and Drug Administration, and safety in the first 
trimester has not been well studied. In addition, invasive proce-
dures should be deferred until the second trimester whenever 
possible, and should always have a strong indication with a care-
ful assessment of risk [14]. Although propofol may be excreted 
in breast milk, at clinical doses the quantity is too small to have 
significant effects on infants.
Recommendation 7: Propofol can be safely used in adult pa-
tients with allergies to eggs (Evidence level: C, Recommendation 
grade: Class IIb).
Recommendation 8: In propofol sedation for elective proce-
dures, the same level of fasting time is required as for general anes-
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thesia (Evidence level: B, Recommendation grade: Class I).
Recommendation 9: The advantages and potential risks of pro-
pofol sedation as well as alternative options (traditional sedation 
or sedation by anesthesiologists) should be provided. Activities 
requiring a high level of psychomotor function (e.g., driving, oper-
ating heavy machinery, or engaging in legally binding decisions) 
should be refrained from for a period of time. Informed consent 
for propofol sedation should also be obtained from the patient or 
his/her legal representative (Evidence level: C, Recommendation 
grade: Class IIa).
Recommendation 10: Intravenous access is required for propo-
fol sedation and should be maintained using a catheter until full 
patient recovery (Evidence level: C, Recommendation grade: Class 
IIa).
Commentary
Allergic reactions to propofol are extremely rare, with an esti-
mated incidence of 1 in 60,000 exposures [15]. Furthermore, pa-
tients who are allergic to eggs typically react to proteins from the 
egg white but not to egg lecithin (from the yolk), which is used 
in propofol. Therefore, the practice of choosing alternatives to 
propofol in patients with known allergies to eggs is not evidence 
based approach [16].
As suggested by the sedation guidelines of the American Col-
lege of Emergency Physicians [17], Recommendation 8 is mainly 
based on the extrapolation of general anesthesia cases in the op-
erating rooms. However, because patient safety was the highest 
priority when formulating the guidelines, the KSA strongly sup-
ports the same fasting time as that used for general anesthesia 
(i.e., 2 h of fasting for clear liquids and 6 h of fasting for milk or 
solids) in propofol sedation for elective cases.
Sedation personnel
Recommendation 11: During propofol sedation, patients should 
be continuously monitored by a medical person who has patient 
sedation as his/her sole task (Evidence level: B, Recommendation 
grade: Class IIa).
Recommendation 12: Indications for propofol sedation by anes-
thesiologists:
(1) American Society of Anesthesiologists (ASA) physical status 
≥ III;
(2) Cases where prolonged procedure (≥ 2 h) is anticipated or 
deep sedation is required in highly invasive procedures;
(3) Patients with potentially difficult airways for intubation or 
mask ventilation;
(4) Patients with a known history of side effects in previous 
sedation or anesthesia (Evidence level: C, Recommendation 
grade: Class IIa); and
(5) Elderly patients aged ≥ 70 years (Evidence level: D, Recom-
mendation grade: Class IIb).
Commentary
These guidelines suggest that the team for propofol sedation 
should consist of a ‘medical doctor in charge of sedation’ and 
‘monitoring medical personnel’. In other words, it is recom-
mended that patients should be continuously monitored by a 
person solely dedicated to propofol sedation.
However, in Korea, a considerable number of propofol seda-
tions have been performed without independent monitoring 
by medical personnel [18]. Although the KSA fully supports 
the necessity of an additional staff member solely for propofol 
sedation for all procedures and patients, Recommendation 11 is 
graded as ‘class IIb’ due to low clinical applicability for prohibit-
ing brief interruptions of monitoring by medical personnel. Al-
lowance for brief interruptions of monitoring due to assistance 
for procedures (particularly in low- or average-risk patients un-
dergoing simple procedures) is a matter of debate, particularly 
in GI endoscopy [5].
Another contentious issue is the safety of propofol sedation 
by non-anesthesiologists in patients of ASA physical status III. 
There is little debate regarding patients of ASA physical status 
IV. Increased ASA class is associated with increased rates of 
sedation-related adverse events; this has been established both 
via large retrospective studies [19] and prospective studies [20]. 
However, as a cut-off criterion for anesthesiology assistance, it 
remains vague. Some GI endoscopy guidelines have expressed 
doubts over the necessity of anesthesiology assistance in patients 
of ASA physical status III undergoing relatively simple proce-
dures [21,22].
Intra-procedural monitoring and equipment
Recommendation 14: All of the patients undergoing propofol 
sedation should be monitored by continuous pulse oximetry and 
automated noninvasive blood pressure measurements during se-
dation, with intervals of a minimum of 5 min. (Evidence level: B, 
Recommendation grade: Class I).
Recommendation 15: During propofol sedation, capnographic 
monitoring of respiratory activity is required in specific situations 
including high-risk patients, intended deep sedation, and long pro-
cedures (≥ 2 h) (Evidence level: B, Recommendation grade: Class 
IIa).
Recommendation 16: Continuous electrocardiography is 
required in patients with a history of cardiovascular and/or pul-
monary disease (Evidence level: C, Recommendation grade: Class 
IIa).
Recommendation 17: All of the cases of deep sedation and 
specific cases of moderate sedation (i.e., sedation for patients with 
cardiovascular and/or pulmonary disease) should only peformed 
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in a setting adequately equipped with a defibrillator (Evidence 
level: C, Recommendation grade: Class IIa).
Recommendation 18: Continuous supplemental oxygen is indi-
cated in every case of propofol sedation, unless specifically contra-
indicated for a particular patient or procedure (Evidence level: A, 
Recommendation grade: Class I).
Commentary
Recommendation 15 is the only one in which we did not reach 
a consensus in the first round of the Delphi consensus process. 
After upgrading ‘class IIa’ from ‘class IIb’, we reached a con-
sensus in the second round. Societies of GI endoscopists have 
recommended that the use of capnography should not manda-
tory, even with propofol sedation [4,5,21,22]. The evidence for 
this stems from several randomized controlled trials [23,24], in 
which use of capnography provided early detection of hypox-
emia, but failed to show any difference in clinical outcomes. 
However, since 2010, the ASA officially stated that capnographic 
monitoring of respiratory activity should be mandatory during 
moderate or deep sedation [25]. The KSA also takes a favorable 
position about the utility of capnography during propofol seda-
tion in that visual inspection of respiratory activity (i.e., another 
possible option) is less reliable and not always possible.
Level of sedation
Recommendation 19: If possible, the level of sedation should be 
maintained below deep sedation (Evidence level: A, Recommenda-
tion grade: Class IIa).
Recommendation 20: There are no pre-determined dose of 
propofol and uniform administration method depending on pro-
cedures. Prior to every sedation, the target level of sedation should 
be determined. During sedation, the dose of propofol should be 
continuously titrated to maintain the target level of sedation based 
on regular monitoring of the depth of sedation (Evidence level: D, 
Recommendation grade: Class IIb).
Commentary
Our meta-analysis indicates that, compared to deep sedation, 
moderate sedation is associated with a decreased risk of desatu-
ration, with similar efficacy profiles (patient and doctor satisfac-
tions, as well as recovery time), as well as risk of recall (Table 4). 
Therefore, unnecessary deep sedation should be avoided.
Because of a lack of analgesic properties of propofol, deep se-
dation is typically required for painful procedures when propo-
fol is used alone for sedation. In such cases, moderate sedation 
is more likely to be achieved by a combination of propofol and 




Continuous variables Categorical variables
No. of  
estimates
Risk ratio  
(95% CI)
No. of  
estimates
Weighted mean  
difference (95% CI) I
2 (%) Pchi2
Recommendation 21: Combination therapy vs. mono-therapy
    Respiratory complication 15 1.12 (0.73, 1.71) 52 0.010
    Hypotension 12 1.23 (0.71, 2.14) 65 0.001
    Total propofol dose 18 0.79 (−1.03, −0.55) 83 < 0.001
    Arrhythmia 10 1.55 (0.97, 2.48) 15 0.301
    Patients satisfaction 8 0.13 (−0.26, 0.52) 90 < 0.001
    Doctor satisfaction 5 0.01 (−0.15, 0.17) 0 0.779
    Recovery time 7 0.27 (−0.46, 0.99) 96 < 0.001
    Procedure time 14 0.03 (−0.08, 0.14) 0 0.489
Recommendation 22: Intermittent bolus injection vs. continuous infusion
    Total propofol dose 6 −0.74 (−1.05, −0.44) 63 0.022
    Number of intervention 2 1.82 (1.30, 2.35) 0 0.721
    Sedation time 3 −3.55 (−5.61, 1.48) 9 0.331
    Recovery time 5 −2.33 (−3.55, −1.11) 45 0.141
    Doctor satisfaction 3 −0.39 (−1.06, 0.28) 86 < 0.001
    Cardiorespiratory complications 6 0.86 (0.48, 1.56) 0 0.972
Recommendation 19: Moderate sedation vs. deep sedation
    Patient satisfaction 3 0.94 (0.86, 1.04) 65 0.059
    Doctor satisfaction 2 0.35 (0.02, 6.95) 100 < 0.001
    Recall 2 5.82 (0.51, 66.48) 60 0.108
    Desaturation 3 0.18 (0.03, 0.99) 0 0.482
    Recovery time 3 −6.77 (−16.21, 2.67) 99 < 0.001
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analgesics [26]. Recommendation 20 was developed based on 
considerations that different patients may require different levels 
of sedation for a given procedure, and may attain varying levels 
of sedation during that procedure.
Propofol administration techniques
Recommendation 21: In GI endoscopic procedures, propofol 
combination therapy with other agents is as effective and safe as 
propofol monotherapy (Evidence level: A, Recommendation grade: 
Class IIa).
Commentary
We performed a meta-analysis of randomized controlled 
trials comparing propofol combination therapy with propofol 
monotherapy for GI endoscopic procedures, both in terms of 
efficacy and safety (Table 4). Our results show that propofol 
combination therapy may enable a significant reduction in the 
total dose of propofol, but without the benefits of reduced risk 
of cardiopulmonary complications (apnea, hypoxemia, hypo-
tension, and arrhythmia) compared to propofol monotherapy. 
Thus, both therapies can be safely used based on the practitio-
ner’s clinical judgment.
In severely agitated patients or in patients undergoing painful 
procedures, a combination of propofol with analgesics and/or 
other sedatives may reduce the required dose of propofol, there-
by resulting in a lower level of sedation [26,27]. Although such 
techniques may also reduce the dose-related adverse effects of 
propofol, the doses of each drug should be carefully controlled 
due to potential synergistic effects on respiratory depression.
Recommendation 22: Intermittent bolus injection, target-
controlled infusion (TCI), and manually controlled infusion (MCI) 
present similar safety profiles. Thus, they may all be applicable 
based on the practitioner’s clinical judgment (Evidence level: A, 
Recommendation grade: Class I).
Commentary
We performed a meta-analysis of randomized controlled 
trials comparing intermittent bolus injection with continuous 
infusion (TCI and MCI) for propofol sedation, both in terms 
of efficacy (total propofol dose, number of intervention, seda-
tion time, recovery time, doctor’s satisfaction) and safety (car-
diorespiratory complications) (Table 4). Our results show that 
intermittent bolus injection may significantly reduce the total 
dose of propofol, sedation time, and recovery time, but without 
the benefits of reduced risk of cardiopulmonary complications 
compared to continuous infusion. In addition, more frequent 
interventions were required by the practitioner during the use of 
intermittent bolus injection compared to continuous infusion.
Other meta-analyses included randomized controlled trials 
for sedation as well as general anesthesia, and showed that TCI 
is associated with higher total doses of propofol than MCI, but 
that both techniques entail similar risks of adverse events [28]. 
Thus, all of the three administration techniques can be safely ap-
plied based on the practitioner’s clinical judgment.
Surveillance during recovery and discharge
Recommendation 23: A minimum recovery time of 30 min is 
required following propofol sedation (Evidence level: B, Recom-
mendation grade: Class IIa).
Recommendation 24: In propofol sedation, the medical person-
nel in charge of recovery require the same level of qualification as 
the monitoring medical personnel (Evidence level: D, Recommen-
dation grade: Class IIb).
Recommendation 25: Discharge criteria, such as the Modified 
Aldrete score or postanesthetic discharge scoring system (PADSS), 
should be applied when discharging patients following propofol 
sedation (Evidence level: A, Recommendation grade: Class I).
Recommendation 26: Because existing discharge criteria do 
not adequately evaluate psychomotor performance, discharged pa-
tients should be in the company of a responsible adult. If possible, 
propofol sedation should be avoided for outpatients without a 
companion (Evidence level: C, Recommendation grade: Class IIb).
Recommendation 27: Prior to discharge from hospital, patients 
should be instructed to refrain from driving for 24 h (Evidence 
level: C, Recommendation grade: Class IIb).
Commentary
The rationale for the minimum recovery time of 30 min is 
that most serious sedation-related complications occur within 
30 min from completion of the procedure [29]. Compared to 
the Modified Aldrete score, PADSS is more suitable for propofol 
sedation, particularly in an outpatient setting [5]. Recent data 
suggest that propofol sedation results in improved psychomotor 
recovery compared to traditional sedation, with 1–6 h being suf-
ficient to drive home safely following propofol sedation [29,30]. 
However, because this issue is one of the important medico-legal 
issues regarding sedation, we conservatively recommended that 
the amount of time a patient should wait before driving follow-
ing propofol sedation is ≥ 24 h.
Sedation-related documentation
Recommendation 28: Documenting of the monitored variables 
should be performed throughout all of the phases of propofol seda-
tion at regular intervals (at least once every 5 min during sedation, 
and at least once every 15 min during recovery) (Evidence level: D, 
Recommendation grade: Class IIa).
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Training in propofol sedation
Recommendation 29: Both medical doctors in charge of seda-
tion and monitoring medical personnel should have attended an 
accredited training course for propofol sedation (one that is ac-
credited by an independent internal sedation committee or an ex-
ternal expert organization), and such a course should include both 
theoretical and practical aspects. Self-training in propofol sedation 
is strongly discouraged (Evidence level: B, Recommendation grade: 
Class I).
Recommendation 30: Qualification for basic life support (BLS) 
should be maintained via periodic participation in an accredited 
program for BLS, both by medical doctors and medical personnel 
in charge of sedation and monitoring (Evidence level: D, Recom-
mendation grade: Class IIa).
Recommendation 31: A qualification (and maintenance there-
of) in advanced cardiac life support (ACLS) is required for medical 
doctors in charge of sedation who will practice in locations where 
an ACLS provider is not immediately available (Evidence level: D, 
Recommendation grade: Class IIa).
Recommendation 32: The first clinical cases of propofol se-
dation performed by an individual should be supervised by an 
anesthesiologist or another doctor with previous experience of > 
100 propofol sedation cases (Evidence level: D, Recommendation 
grade: Class III).
Commentary
The doctor in charge of propofol sedation has the overall re-
sponsibility for sedation, and must have completed a theoretical 
and practical training course in propofol sedation. This includes 
pharmacological knowledge of propofol; familiarity with the 
various levels of sedation; and knowledge, recognition, and 
treatment of anticipated adverse events including cardiopulmo-
nary resuscitation, maintaining open airways, intubation, and 
assisted ventilation [3,5,27,31,32]. Those monitoring medical 
personnel who will assist in propofol administration or perform 
patient monitoring must receive structured, relevant training in 
propofol sedation and basic airway management. 
In this regard, the KMA recommends fulfilling a prior edu-
cational program for all of the practitioners responsible for 
propofol sedation. The KMA will prepare an official educational 
program (a 3 h theoretical training course and a 1 h ethical 
and legal lecture) in collaboration with the KSA. We believe 
that such a KMA policy will enhance patient safety in propofol 
sedation, although it lacks a practical training course and educa-
tional programs for other medical personnel.
Issues relating to the abuse potential of propofol
Recommendation 33: Propofol sedation should not be per-
formed for therapeutic purposes. In some patients, repeated pro-
pofol sedation over a relatively short period of time may lead to 
psychological dependence. Therefore, in cases of repeated propofol 
sedation over a relatively short period, the practitioner should 
carefully evaluate the presence of psychological dependence on 
propofol and inform the patient that it is a potential risk (Evidence 
level: C, Recommendation grade: Class IIa).
Commentary
The first reported case of propofol abuse was in 1992 [33], 
and many abuse cases of propofol among healthcare providers 
have been reported since that time. In contrast to other coun-
tries, a significant portion of propofol abuse in Korea has been 
documented among laypeople [34]. Thus, it was eventually des-
ignated as a controlled substance in Korea in February 2011. 
The abuse potential of propofol is strongly supported by 
molecular, animal, and clinical pharmacological data [34]. It 
appears to result from psychological dependence, rather than 
physiological dependence. Thus, when a patient receives propo-
fol sedation repeatedly over a relatively short period of time, it 
is important for the practitioner to inform the patient of the po-
tential for propofol dependence, and to carefully assess the pres-
ence of a psychological dependence on propofol. To date, only 
Xu et al. [36] has evaluated the efficacy of propofol sedation for 
its therapeutic effects (in their study, refractory chronic primary 
insomnia). However, considering the cardiopulmonary risks of 
short-term use of propofol and the potential for dependence in 
longer-term use, propofol sedation itself should not be used for 
therapeutic purposes.
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